Full-Time
Molecular Technologist I-IV: Sunday-Wednesday
AI-driven precision medicine through clinical and molecular data analysis
Entry, Junior
Raleigh, NC, USA + 1 more
- One of the following educational requirements:
- MS in medical technology, clinical laboratory science, chemical, physical or biological science and 1 year pertinent clinical laboratory experience with molecular biology
- BS/BA in medical technology, clinical laboratory science, chemical, physical or biological science and 1 year of pertinent clinical lab experience in molecular biology
- Excellent communication skills
- Experience with next-generation sequencing
- Work in a CLIA/CAP high-complexity laboratory
- Experience with robotics and automated liquid handling systems
- Knowledge of LIMS platforms and various computer systems
- Work with a cutting-edge genomics workflow to provide high-quality next-generation sequencing data with rapid turnaround times in a clinical laboratory
- Perform routine testing, quality control, calibration, maintenance and proficiency testing in accordance with current laboratory procedures
- Perform complex molecular-based procedures with a high degree of quality and in accordance with established protocols
- Perform next-generation sequencing, including nucleic acid extraction, DNA/RNA quantification and qualification, NGS library preparation, probe hybridization, probe/library capture, library cleanup and quantification, loading sequencing libraries onto the Illumina Nextseq, HiSeq4000, and Novaseq
- Sterilizing laboratory equipment and workspaces as assigned
- Entering clinical patient data into the Laboratory Information Management system
- Obtain 12 continuing education hours in the field of oncology or molecular biology
- Maintain competency to perform all assigned molecular biology protocols in accordance with CAP, CLIA, NYSDOH regulations
- Work the Sunday-Wednesday, 2pm Shift
Tempus Labs, Inc. is a leader in precision medicine, leveraging artificial intelligence to analyze vast clinical and molecular data, enabling physicians to deliver personalized, data-driven care. The company's advanced machine learning platform and unique solution sets facilitate the discovery, development, and delivery of optimized therapeutic options for patients. With a focus on extensive molecular profiling, Tempus has developed a robust pan-cancer tumor organoid platform and validated a liquid biopsy assay, demonstrating their commitment to transforming personalized patient care and their position at the forefront of the healthcare industry.
Company Stage
Series G
Total Funding
$1.3B
Headquarters
Chicago, Illinois
Founded
2015